Please assess the completion status of the following clinical trial:

Trial Title: A Study to Determine the Efficacy of Lenalidomide Versus Investigator's Choice in Patients With Relapsed or Refractory Mantle Cell Lymphoma (MCL)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Biopsy proven mantle cell lymphoma~* Patients who are refractory to their regimen or have relapsed once, twice or up to three times and who have documented progressive disease~* Eastern Cooperative Oncology Group (ECOG) performance score 0,1, or 2~* Willing to follow pregnancy precaution~Exclusion Criteria:~* Any of the following laboratory abnormalities~* Absolute neutrophil count (ANC) \< 1,500 cells/mm\^3 (1.5 x 10\^9/L)~* Platelet count \< 60,000/mm\^3 (60 x 10\^9/L)~* Serum aspartate transaminase/serum glutamic oxaloacetic transaminase(AST/SGOT) or alanine transaminase/serum glutamic pyruvic transaminase (ALT/SGPT) \>3.0 x upper limit or normal (ULN), except patients with documented liver involvement by lymphoma~* Serum total bilirubin \> 1.5 x ULN, except in case of Gilbert's Syndrome and documented liver involvement by lymphoma.~* Calculated creatinine clearance (Cockcroft-Gault formula) of \< 30 mL/min~* History of active central nervous system (CNS) lymphoma within the previous 3 months~* Subjects not willing to take deep venous thrombosis (DVT) prophylaxis~* Known seropositive for or active viral infection with human immunodeficiency virus (HIV), hepatitis B virus (HBV) or hepatitis C virus (HCV). Patients who are sero-positive because of hepatitis B virus vaccine are eligible

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Lenalidomide (Type: EXPERIMENTAL): Lenalidomide
- Investigators choice single agent (Type: ACTIVE_COMPARATOR): Investigators choice single agent - Chlorambucil, Rituximab, Cytarabine, Gemcitabine, Fludarabine

Based on this trial design, predict the completion outcome and termination type (if applicable).